BTB Therapeutics, Inc. filed an amended Form D with the Securities and Exchange Commission on 2025-12-01.
BTB Therapeutics, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on December 1, 2025. The filing reports $8.90M sold. Its industry group is Pharmaceuticals. It names Takashi Kiyoizumi (Executive Officer, Director), Nobuhiro Yagi (Director), Masatoshi Hagiwara (Director) (SEC Form D/A, December 1, 2025).
Is this your company?
Sell to companies like BTB Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-12-01 · the record
Pitching, partnering or investing alongside them? See who really runs and owns BTB Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind BTB Therapeutics, Inc., from the filings we hold.
Pharmaceuticals raises by companies based in California, filed in December 2025, largest first.
Get an email when BTB Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when BTB Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch BTB Therapeutics, Inc. →Get the full cited report on BTB Therapeutics, Inc.
What the filing shows about BTB Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on BTB Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives BTB Therapeutics, Inc.'s address as 26281 Wyndemere Court, Escondido, CA 92026.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for BTB Therapeutics, Inc. →
Amended on 2026-08-12: the offering size changed from $7,402,704 to $10,402,704; the amount sold changed from $3,402,704 to $8,902,204. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
BTB Therapeutics, Inc. is a registered filer with the SEC (CIK 2055053) and has filed since 2025-02-05. 2 filings are on record, the latest on 2025-12-01.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
BTB Therapeutics, Inc.'s Form D of 2025-12-01 names Takashi Kiyoizumi, Nobuhiro Yagi, Masatoshi Hagiwara and 1 more as its officers, directors or promoters.
Its new offerings report $6.73M sold across 2 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week. The dot is this raise, $8.90M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Takashi Kiyoizumi is named as Executive Officer and Director on the Form D that BTB Therapeutics, Inc. filed with the SEC on 1 December 2025, one of 5 people that filing names.
Nobuhiro Yagi is named as Director on the Form D that BTB Therapeutics, Inc. filed with the SEC on 1 December 2025, one of 5 people that filing names.
Masatoshi Hagiwara is named as Director on the Form D that BTB Therapeutics, Inc. filed with the SEC on 1 December 2025, one of 5 people that filing names.
David Snyder is named as Director on the Form D that BTB Therapeutics, Inc. filed with the SEC on 1 December 2025, one of 5 people that filing names.
Sidney Yee is named as Director on the Form D that BTB Therapeutics, Inc. filed with the SEC on 1 December 2025, one of 5 people that filing names.
5 people named on the filing — 1 holding an executive role and 4 as directors only.
Named as of the 2025-12-01 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about BTB Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on BTB Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BTB Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist BTB Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind BTB Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for BTB Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in San Diego
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/btb-therapeutics-inc-form-d-25000001